B. Uluata Dayanç Et Al. , "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue," In Lung Cancer Diagnosis and Treatment , Londrina: Springer, 2024, pp.217-247.
Uluata Dayanç, B. Et Al. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. 2024. In Lung Cancer Diagnosis and Treatment , Springer, Londrina, 217-247.
Uluata Dayanç, B., Eriş, S., & Şentürk, Ş., (2024). Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. Lung Cancer Diagnosis and Treatment (pp.217-247), Londrina: Springer.
Uluata Dayanç, Bengisu, SUDE ERİŞ, And ŞERİF ŞENTÜRK. "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue." In Lung Cancer Diagnosis and Treatment , 217-247. Londrina: Springer, 2024
Uluata Dayanç, Bengisu U. Et Al. "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue." Lung Cancer Diagnosis and Treatment , Springer, 2024, pp.217-247.
Uluata Dayanç, B. Eriş, S. And Şentürk, Ş. (2024) "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue", Lung Cancer Diagnosis and Treatment . Londrina: Springer.
@bookchapter{bookchapter, author ={Bengisu Uluata Dayanç Et Al. }, chaptertitle={Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue}, booktitle={ Lung Cancer Diagnosis and Treatment}, publisher={Springer}, city={Londrina},year={2024} }